James Overell

3.6k total citations · 1 hit paper
28 papers, 1.3k citations indexed

About

James Overell is a scholar working on Pathology and Forensic Medicine, Neurology and Cellular and Molecular Neuroscience. According to data from OpenAlex, James Overell has authored 28 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 9 papers in Neurology and 5 papers in Cellular and Molecular Neuroscience. Recurrent topics in James Overell's work include Multiple Sclerosis Research Studies (12 papers), Peripheral Neuropathies and Disorders (6 papers) and Hereditary Neurological Disorders (5 papers). James Overell is often cited by papers focused on Multiple Sclerosis Research Studies (12 papers), Peripheral Neuropathies and Disorders (6 papers) and Hereditary Neurological Disorders (5 papers). James Overell collaborates with scholars based in United Kingdom, Switzerland and United States. James Overell's co-authors include K. R. Lees, I Bone, Hugh J. Willison, Sarah McGlasson, Masaaki Odaka, Nobuhiro Yuki, David Hunt, Sarah Barry, Amanda Fitzpatrick and Kennedy R. Lees and has published in prestigious journals such as The Lancet, Neurology and The Lancet Neurology.

In The Last Decade

James Overell

23 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interatrial septal abnormalities and stroke

2000 681 citations James Overell, I Bone et al. Neurology profile →

Peers

Countries citing papers authored by James Overell

Since Specialization

Citations

This map shows the geographic impact of James Overell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Overell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Overell more than expected).

Fields of papers citing papers by James Overell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Overell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Overell. The network helps show where James Overell may publish in the future.

Co-authorship network of co-authors of James Overell

This figure shows the co-authorship network connecting the top 25 collaborators of James Overell. A scholar is included among the top collaborators of James Overell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Overell. James Overell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials 2025 ·Multiple Sclerosis and Related Disorders ·Ralph H. B. Benedict, Ludwig Kappos, Aaron Miller, Hans-Peter Hartung, James Overell, Jinglan Pei, Frank Dahlke, Corrado Bernasconi, Harold Koendgen, Qing Wang, (unknown), Stanley Cohan	1
2	Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study 2025 ·Multiple Sclerosis Journal ·(unknown), (unknown), (unknown), (unknown), Nicklas Linz, (unknown), Chris Chatham, James Overell, (unknown), Johannes Tröger, Anja Dillenseger, Björn Tackenberg, Tjalf Ziemssen	0
3	Detecting fatigue in multiple sclerosis through automatic speech analysis 2024 ·Frontiers in Human Neuroscience ·Marcelo Fernandes Pacheco Dias, (unknown), (unknown), (unknown), (unknown), (unknown), Nicklas Linz, James Overell, (unknown), Johannes Tröger, (unknown), Anja Dillenseger, Björn Tackenberg, (unknown)	2
4	Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO) 2024 ·Frontiers in Neurology ·Soon‐Tae Lee, Hesham Abboud, Sarosh R. Irani, Hideto Nakajima, Amanda L. Piquet, Sean J. Pittock, E. Ann Yeh, Jiawei Wang, Sharmila Rajan, James Overell, Jillian Smith, (unknown), Muna El-Khairi, (unknown), Jeffrey M. Gelfand	8
5	Reliability and External Validity of Digital Passive Gait Tracking in MS (P6-6.008) 2024 ·Neurology ·(unknown), Barbara Willekens, Bertrand Degos, Damien Ricard, Vincent Van Pesch, (unknown), (unknown), Hui Li, Émilie Lommers, (unknown), (unknown), James Overell, Céline Cluzeau, (unknown), Laurent Servais	0
6	Opioid prescribing patterns following common general surgery procedures in the Bay of Plenty, New Zealand 2023 ·ANZ Journal of Surgery ·(unknown), James Overell, Jeremy Rossaak	0
7	PND55 Socioeconomic Value of Ocrelizumab in the Treatment of Patients with Primary Progressive Multiple Sclerosis 2020 ·Value in Health ·(unknown), (unknown), G Marcelli, (unknown), James Overell	0
8	PND47 Socioeconomic Value of Ocrelizumab in the Treatment of Patients with Relapsing Forms of Multiple Sclerosis 2020 ·Value in Health ·(unknown), (unknown), G Marcelli, (unknown), James Overell	0
9	Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial 2020 ·The Lancet Neurology ·Jerry S. Wolinsky, Douglas L. Arnold, Bruno Brochet, Hans-Peter Hartung, Xavier Montalbán, Robert T. Naismith, Marianna Manfrini, James Overell, Harold Koendgen, Annette Sauter, (unknown), Stanislas Hubeaux, Ludwig Kappos, Stephen L. Hauser	103
10	Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case–control studies 2019 ·Journal of Neurology Neurosurgery & Psychiatry ·(unknown), Sarah McGlasson, David Hunt, James Overell	62
11	Towards a More User-Friendly Medication Information Delivery to People Living with Multiple Sclerosis: A Case Study with Alemtuzumab 2019 ·Advances in experimental medicine and biology ·(unknown), Matthieu Poyade, James Overell	5
12	Factors influencing multiple sclerosis disease-modifying treatment prescribing decisions in the United Kingdom: A qualitative interview study 2018 ·Multiple Sclerosis and Related Disorders ·Elaine Cameron, David Rog, Gavin McDonnell, James Overell, Owen Pearson, David French	17
13	Peripheral neuropathy: pattern recognition for the pragmatist 2012 ·Postgraduate Medical Journal ·James Overell	3
14	An open label clinical trial of complement inhibition in multifocal motor neuropathy 2011 ·Journal of the Peripheral Nervous System ·Amanda Fitzpatrick, (unknown), Sarah Barry, (unknown), James Overell, Hugh J. Willison	73
15	Peripheral neuropathy: pattern recognition for the pragmatist 2011 ·Practical Neurology ·James Overell	4
16	Variant CJD in an individual heterozygous for PRNP codon 129 2009 ·The Lancet ·Diego Kaski, Simon Mead, Harpreet Hyare, Sarah Cooper, Ravi Jampana, James Overell, Richard Knight, John Collinge, Peter Rudge	70
17	Recent developments in Miller Fisher syndrome and related disorders 2005 ·Current Opinion in Neurology ·James Overell, Hugh J. Willison	58
18	Effect of Perindopril on Cerebral and Renal Perfusion on Normotensives in Mild Early Ischaemic Stroke: A Randomized Controlled Trial 2004 ·Cerebrovascular Diseases ·(unknown), James Overell, (unknown), (unknown), Kennedy R. Lees	30
19	The effect of losartan on global and focal cerebral perfusion and on renal function in hypertensives in mild early ischaemic stroke 2004 ·Journal of Hypertension ·(unknown), James Overell, (unknown), (unknown), John L. Reid, Kennedy R. Lees	23
20	An aid to predicting prognosis in patients with non-traumatic coma at one day 2001 ·Journal of Neurology Neurosurgery & Psychiatry ·James Overell, I Bone, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact